Session » RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0766

ACPA and Cholesterol Titers as Predictors of Good Clinical Response at One Year in an Argentine Cohort

9:00AM-11:00AM: Abstract Number: 0758

Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0761

Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0762

Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score

9:00AM-11:00AM: Abstract Number: 0744

Circulating Fibroblast Growth Factor-21 Levels in Rheumatoid Arthritis: Associations with Disease Characteristics, Body Composition, and Physical Functioning

9:00AM-11:00AM: Abstract Number: 0745

Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment

9:00AM-11:00AM: Abstract Number: 0755

Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0746

HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0765

High Disease Activity at Baseline and Seropositivity Are Associated with Treatment Response at One Year Post Synovial Biopsy in RA Patients

9:00AM-11:00AM: Abstract Number: 0743

Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 0756

Increased Risk of Hospitalization in Patients with RA Who Are ACPA Positive and Shared Epitope Positive

9:00AM-11:00AM: Abstract Number: 0747

Isotope-Labeling-LC-MS-based Metabolic Profiling of Multiple Serum Sample Sets for the Discovery of High-confidence Rheumatoid Arthritis Biomarkers

9:00AM-11:00AM: Abstract Number: 0748

Joint Space Narrowing Precedes Erosive Radiographic Damage in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0749

Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)

9:00AM-11:00AM: Abstract Number: 0750

Nuclei Detection in Rheumatoid Arthritis Synovial Tissue Using Artificial Intelligence

9:00AM-11:00AM: Abstract Number: 0763

Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0759

Presence of Ultrasound Imaging Biomarkers Are Good Predictors of Arthritis Development in a Population at Risk for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0751

Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment

9:00AM-11:00AM: Abstract Number: 0752

Serum Proteomics Implicates Neutrophil Degranulation in Rheumatoid Arthritis Disease Activity

9:00AM-11:00AM: Abstract Number: 0757

Sunlight Exposure, Sun-protective Behaviour, and Anti-citrullinated Protein Antibody Positivity: A General Population-based Study in Quebec, Canada

9:00AM-11:00AM: Abstract Number: 0753

Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort

9:00AM-11:00AM: Abstract Number: 0754

The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs

9:00AM-11:00AM: Abstract Number: 0764

Uncovering Novel Biomarkers for Rheumatoid Arthritis from Feature Selection and Machine Learning Approaches on Synovium and Blood Gene Expression Data

9:00AM-11:00AM: Abstract Number: 0760

X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].